Specialised Therapeutics Asia has announced that its therapy to treat rare gastrointestinal stromal tumours, QINLOCK (ripretinib), has been approved for use in New Zealand and will now be considered for funding by Pharmac.
New Zealand approval for Specialised Therapeutics' cancer therapy
January 20, 2023 Latest NewsBioPharma
Latest Video
New Stories
-
The 'Week in Review' - 27 January
January 27, 2023 - - Podcast -
Forget about experts and terms of reference until we get a transparent process
January 27, 2023 - - Latest News -
Australia Day recognition for senior officials and pharmacy leaders
January 27, 2023 - - Latest News -
Is this a change of heart from the former health department secretary?
January 27, 2023 - - Latest News -
New chair for Australian genomics industry organisation
January 26, 2023 - - Australian Biotech -
MEDLAB receives Import Certificate from UK Home Office for NanaBis
January 26, 2023 - - Australian Biotech -
Alterity Therapeutics launches ATH434 Phase 2 clinical trial in Italy
January 26, 2023 - - Australian Biotech